RxDoctor Payments Data

Matthew Deeths, MD

Dermatology · Grand Junction, CONPI 1750345690

Payments from drug & device makers

$1,329in general payments, 2019–2025

Across 59 payments — averaging $22.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$552
  • Novartis$130
  • Biofrontera Inc.$119
  • Sun Pharmaceutical Industries Inc.$85
  • Incyte Corporation$69
  • UCB, Inc.$61
  • plus $312 from 9 others

What the payments were for

  • Food & beverage$1,329100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,329 in reported general payments places this provider in the 40th percentile of 280 dermatology providers in Colorado.

See all dermatology providers in Colorado

Medicare billing

Part B allowed, 2024
$339,512
Medicare patients
822
Services billed
10,920

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf)Adalimumab13$114,992
Dupixent PenDupilumab28$98,527
Clobetasol Propionate65$6,314
Acitretin15$4,665
Triamcinolone Acetonide100$1,925
MethotrexateMethotrexate Sodium61$1,410
Mycophenolate Mofetil16$1,382
Metronidazole16$1,353
Fluorouracil18$1,092
Doxycycline Hyclate42$989
ValacyclovirValacyclovir Hcl16$648
Fluocinonide13$385
Terbinafine Hcl23$180
Prednisone13$81

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieHumira(Cf)$552$114,99213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 280 dermatology providers in Colorado.

Other dermatology in Grand Junction

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →